Insulin resistance and steatosis in hepatitis C virus infection

Por Zekry, A, McHutchison, J G, Diehl, A M
Publicado em 2005

Estimating future hepatitis C morbidity, mortality, and costs in the United States.

Por Wong, J B, McQuillan, G M, McHutchison, J G, Poynard, T
Publicado em 2000

Bedside inoculation of blood culture bottles with ascitic fluid is superior to delayed inoculation in the detection of spontaneous bacterial peritonitis.

Por Runyon, B A, Antillon, M R, Akriviadis, E A, McHutchison, J G
Publicado em 1990

Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection.

Por Rehermann, B, Chang, K M, McHutchison, J G, Kokka, R, Houghton, M, Chisari, F V
Publicado em 1996

Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus.

Por Chang, K M, Rehermann, B, McHutchison, J G, Pasquinelli, C, Southwood, S, Sette, A, Chisari, F V
Publicado em 1997

Achieving sustained virologic response after interferon‐free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis

Por Meissner, E. G., Kohli, A., Virtaneva, K., Sturdevant, D., Martens, C., Porcella, S. F., McHutchison, J. G., Masur, H., Kottilil, S.
Publicado no J Viral Hepat (2016)

Comprehensive Biomarker Discovery Platform Reveals Qualified MRM Assay for Prediction of INF/Ribavirin Treatment Response in Hepatitis C Patients

Por Dubois, L.G., Patel, K., Lucas, J.E., McCarthy, J., McHutchison, J.G., Moseley, M.A., Thompson, J.W.
Publicado em 2011

Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif.

Por Cerny, A, McHutchison, J G, Pasquinelli, C, Brown, M E, Brothers, M A, Grabscheid, B, Fowler, P, Houghton, M, Chisari, F V
Publicado em 1995

Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C

Por Siebert, U, Sroczynski, G, Rossol, S, Wasem, J, Ravens-Sieberer, U, Kurth, B M, Manns, M P, McHutchison, J G, Wong, J B
Publicado em 2003

Antiviral treatment initiation costs in chronic hepatitis C

Por Siebert, U, Wasem, J, Rossol, S, Sroczynski, G, Aidelsburger, P, Ravens-Sieberer, U, Kurth, B M, Manns, M P, McHutchison, J G, Wong, J B
Publicado em 2005

Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C

Por Patel, K., Jhaveri, R., George, J., Qiang, G., Kenedi, C., Brown, K., Cates, C., Zekry, A., Tillmann, H. L., Elliott, L., Kilaru, R., Albrecht, J., Conrad, A., McHutchison, J. G
Publicado em 2011

Randomised clinical trial: a phase 1, dose‐ranging study of the anti‐matrix metalloproteinase‐9 monoclonal antibody GS‐5745 versus placebo for ulcerative colitis

Por Sandborn, W. J., Bhandari, B. R., Fogel, R., Onken, J., Yen, E., Zhao, X., Jiang, Z., Ge, D., Xin, Y., Ye, Z., French, D., Silverman, J. A., Kanwar, B., Subramanian, G. M., McHutchison, J. G., Lee, S. D., Shackelton, L. M., Pai, R. K., Levesque, B. G., Feagan, B. G.
Publicado no Aliment Pharmacol Ther (2016)

Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the a...

Por Clark, P. J., Thompson, A. J., Zhu, M., Vock, D. M., Zhu, Q., Ge, D., Patel, K., Harrison, S. A., Urban, T. J., Naggie, S., Fellay, J., Tillmann, H. L., Shianna, K., Noviello, S., Pedicone, L. D., Esteban, R., Kwo, P., Sulkowski, M. S., Afdhal, N., Albrecht, J. K., Goldstein, D. B., McHutchison, J. G., Muir, A. J.
Publicado em 2012